drugset / Trial / NCT06191991
A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)
Non-randomizedSequentialOpen-labelOther
Summary
This Phase 1 study consists of two parts, all conducted in healthy volunteers (HVs). In Parts 1 and 2, the drug-drug interaction (DDI) potential of ALG-055009 will be explored, where subjects will be assigned to receive multiple doses of ALG-055009 and 2 single doses of one of the following concomitant drugs: atorvastatin (Part 1), or rosuvastatin (Part 2, optional).
Timeline
- Start
- 2023-11-03
- Primary completion
- 2023-11-27
- Completion
- 2023-12-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALG-055009 | Unknown | 0.9 mg | Oral |
| Subject | Atorvastatin | Small molecule | 40 mg | Oral |
| Subject | Rosuvastatin | Small molecule | 10 mg | Oral |
Indications
No indication recorded.